MAXONA Pharmaceuticals is a clinical-stage drug developer advancing MAX-001, a patent-protected, non-opioid and non-NSAID treatment candidate for acute and chronic pain. Founded by President and CEO Shawn Fatholahi, the company draws on a leadership team with deep experience in neuroscience, formulation, clinical development and regulatory affairs. MAX-001 has completed its IND-enabling studies and Phase I trials, with Phase II development expected to be completed in 2026.
MindLabFounded by pharmaceutical and legal executive Larry Raoul James, MindLab is a pain-therapy company developing treatments intended to deliver morphine-level relief with less risk of abuse-related harm. Its work centers on MLB-001, a proposed morphine replacement for patients who need effective pain control without the consequences associated with conventional opioid therapy.New York, NY
Vitalis TherapeuticsVitalis Therapeutics is a physician-researcher-founded pharmaceutical company developing non-opioid therapies for acute post-operative pain, with an initial focus on oral ketamine for patients recovering from total knee replacement. Its lead candidate, VS-1, is in planning for a Phase 2a clinical trial and is designed to reduce opioid use while supporting earlier mobility and recovery at home. The company works with orthopedic surgeons and uses a compounding-pharmacy pathway to pursue early access for interested patients.
Syntho Pharmaceuticals, IncFounded in 1999 by pharmacist Muhammed Malik and Hosneara Malik, Syntho Pharmaceuticals is a family-run Farmingdale manufacturer developing and producing branded and generic medicines. Now led by Hosneara as president and their daughter Tithi in operations and regulatory management, the company combines in-house analytical testing with FDA-registered, DEA Schedule CIII–CV licensed manufacturing and packaging capabilities. Its team works across development, quality, production, and regulatory support for pharmaceutical clients.FARMINGDALE, NY
Egalet CorporationEgalet Corporation is a fully integrated specialty pharmaceutical company developing and commercializing medicines for acute and chronic pain, with a particular focus on oral products designed to deter prescription-drug abuse. Its Guardian Technology uses physical and chemical barriers alongside tailored drug release, while the company’s manufacturing approach combines pharmaceutical production with plastic injection molding. Egalet has marketed OXAYDO and SPRIX and has described late-stage abuse-deterrent opioid candidates in its pipeline.WAYNE, PA